← Back to Search

Hormone Therapy

Postmenopausal women for Follicle Stimulating Hormone

Phase 2
Waitlist Available
Research Sponsored by Eastern Virginia Medical School
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 weeks for each participant
Awards & highlights

Study Summary

This study is evaluating whether a ratio of two hormones may be a better indicator of fertility than the current standard of measuring one hormone.

Eligible Conditions
  • Follicle Stimulating Hormone
  • Estradiol Effect
  • Urinary FSH21/FSH24 Ratio

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 weeks for each participant
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 weeks for each participant for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The levels of serum estradiol and FSH in young women versus postmenopausal women.
The ratio of urinary FSH21/FSH24 and total FSH levels in urine of young women versus postmenopausal women.

Trial Design

2Treatment groups
Active Control
Group I: Postmenopausal womenActive Control1 Intervention
Participants will bring into clinic their first voided urine of the day on assigned days 1, 4 and 7 in a urinary collection kit that will be given. A urine dip stick will be performed on the samples. Each time they bring in a sample, they will have a serum blood draw for estradiol and FSH. The participants will then be started on EstroGel© for 14 days from day 7-21. During that time that they are on EstroGel©, the participants will bring into clinic their first voided urine of the day on assigned days 15, 18, and 21 in a urinary collection kit that will be given. A urine dip stick will be performed on the samples. Each time they bring in a sample, they will have a serum blood draw for estradiol and FSH. After the last urinary collection and blood draw, they will discontinue the EstroGel and be started on micronized progesterone if they have a uterus for 12 days.
Group II: Premenopausal womenActive Control1 Intervention
Participants will bring into clinic their first voided urine of the day on cycle days 9, 12 and 15 in a urinary collection kit that will be given. A urine dip stick will be performed on the samples. Each time they bring in a sample, they will have a serum blood draw for estradiol and FSH.

Find a Location

Who is running the clinical trial?

Wichita State UniversityUNKNOWN
3 Previous Clinical Trials
414 Total Patients Enrolled
Eastern Virginia Medical SchoolLead Sponsor
69 Previous Clinical Trials
14,441 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Follicle Stimulating Hormone (FSH) Glycosylation in Women: Effect of Estradiol
Reem Sabouni 2019. "Follicle Stimulating Hormone (FSH) Glycosylation in Women: Effect of Estradiol". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03868202.
All > Acth
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top